APO-GLICLAZIDE MR TABLET (EXTENDED-RELEASE)
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
27-12-2019
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
GLICLAZIDE
から入手可能:
APOTEX INC
ATCコード:
A10BB09
INN（国際名）:
GLICLAZIDE
投薬量:
30MG
医薬品形態:
TABLET (EXTENDED-RELEASE)
構図:
GLICLAZIDE 30MG
投与経路:
ORAL
パッケージ内のユニット:
100
処方タイプ:
Prescription
治療領域:
SULFONYLUREAS
製品概要:
Active ingredient group (AIG) number: 0119934002; AHFS:
認証ステータス:
APPROVED
承認日:
2008-06-04
製品の特徴
PRODUCT MONOGRAPH
Pr
APO-GLICLAZIDE MR
GLICLAZIDE
MODIFIED-RELEASE TABLETS
30 MG
MODIFIED-RELEASE BREAKABLE TABLETS
60 MG
Hypoglycemic sulfonylurea - Oral antidiabetic agent
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
December 27, 2019
TORONTO ONTARIO
M9L 1T9
CONTROL NO: 233440
Page 2 of 43
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
.................................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
4
WARNINGS AND PRECAUTIONS
..........................................................................................................
4
ADVERSE REACTIONS
............................................................................................................................
8
DRUG INTERACTIONS
..........................................................................................................................
12
DOSAGE AND ADMINISTRATION
......................................................................................................
15
OVERDOSAGE
.........................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
17
STORAGE AND STABILITY
..................................................................................................................
20
SPECIAL HANDLING INSTRUCTIONS
................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
20
PART II: SCI
完全なドキュメントを読む
